Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC chlamydia test

This article was originally published in The Tan Sheet

Executive Summary

Antioch, Calif.-based Zonda intends to eventually seek approval to market itsHandiLab-C over-the-counter chlamydia test in the U.S., according to a spokesperson for CLX Investment, which holds 31% equity interest in the California firm. Currently, the HandiLab-C test is the only OTC test for chlamydia that carries the CE mark, which signifies the product complies with relevant European Union health, safety and environmental protection requirements, according to CLX. Zonda recently entered into a distribution agreement to introduce the test in Turkey, according to a Sept. 19 release from CLX. "In fairly short order, we expect that the HandiLab-C will be found on pharmacy shelves in virtually every country in Europe," CLX Chairman and CEO Robert McCoy says...

You may also be interested in...



UK IVDs Firms Working Flat Out On COVID-19 Tests, As Govt Promises Test Capacity Increase

Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

Topics

UsernamePublicRestriction

Register

PS099787

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel